Specialty Pharma Journal Specialty, Precision & Technology
NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE:PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, compared to placebo, in patients with moderate to severe alopecia areata (AA), an autoimmune disease characterized by hair loss and …
Tag Archives: autoimmune disease
September, 2018
September, 2017
-
14 September
Alexion’s Soliris Demonstrates Positive Results in Phase 3 Open-Label Extension Study in Refractory Generalized Myasthenia Gravis
NEW HAVEN, Conn.–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) announced today results from an interim analysis of an ongoing Phase 3 open-label extension study of the pivotal, placebo-controlled REGAIN study of Soliris® (eculizumab) for the treatment of patients with refractory generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. The new results …
January, 2017
-
24 January
FDA Grants Priority Review to Genentech’s Actemra for Giant Cell Arteritis
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the company’s Supplemental Biologics License Application (sBLA) for Actemra® (tocilizumab) for the treatment of GCA, a chronic, potentially life-threatening autoimmune condition. The …
December, 2016
-
16 December
Investigating Kidney Biomarkers to Track Lupus
ANN ARBOR, Mich. – Lupus, a chronic autoimmune disease, can wreak havoc on an affected individual’s body through inflammation, pain and even damage of the skin, joints and organs. To try to better understand how the disease begins and progresses, researchers at the University of Michigan investigated whether kidney biomarkers …
July, 2016
-
20 July
An Antibody-Based Drug for Multiple Sclerosis
Inserm Unit U919, directed by Prof. Denis Vivien (“Serine Proteases and Physiopathology of the Neurovascular Unit”) has developed an antibody with potential therapeutic effects against multiple sclerosis. The study, directed by Fabian Docagne and published in Brain, paves the way for a new strategy to control the disease. Multiple sclerosis …
March, 2016
-
21 March
Lupus Study Shows Precision Medicine’s Potential to Define the Genetics of Autoimmune Disease
DALLAS – March 18, 2016 – Demonstrating the potential of precision medicine, an international study based at UT Southwestern Medical Center used next-generation DNA sequencing technology to identify more than 1,000 gene variants that affect susceptibility to systemic lupus erythematosus (SLE). Precision medicine is an emerging field that aims to deliver …
December, 2015
-
30 December
Benefits of Tight Control
Psoriasis, a type of autoimmune disease, afflicts more than 7.5 million Americans, causing itchy or sore patches of thick, reddened skin covered with silvery scales. While this disease is most likely to develop in people 15-25 years old, after about a decade of having psoriasis, some people also develop psoriatic …
-
14 December
Akaal Pharma’s Drug Candidate Demonstrates Superior Safety & Comparable Efficacy Compared to Gilenya for Treatment of MS
MELBOURNE, Australia & SAN DIEGO–(BUSINESS WIRE)–Akaal Pharma, a clinical-stage drug discovery and development company, today announced the publication of preclinical studies of safety and efficacy of its novel small molecule drug candidate AKP-11 in comparison with Gilenya (Fingolimod, FTY-720). Gilenya is a FDA approved oral drug for the treatment of …
November, 2015
-
11 November
AstraZeneca’s Lupus Drug Succeeds in Mid-Stage Study
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present positive data today from the Phase II trial of anifrolumab for the treatment of moderate-to-severe systemic lupus erythematosus (SLE or lupus) at the American College of Rheumatology (ACR) 2015 Annual Scientific Meeting in San Francisco. Trial results …